Valuation: CROSSJECT

Market Cap 86.02M 100M 80.7M 73.74M 139M 9.57B 140M 955M 370M 4.83B 376M 368M 15.97B P/E 2026 *
3.85x
P/E 2027 * 3.04x
Enterprise Value 68.12M 79.39M 63.91M 58.39M 110M 7.57B 111M 756M 293M 3.83B 298M 292M 12.64B EV / Sales 2026 *
1.12x
EV / Sales 2027 * 0.92x
Free-Float
91.83%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 2001-08-07
Director of Finance/CFO - 2026-03-24
Corporate Officer/Principal - 2024-08-19
Director TitleAgeSince
Chairman 67 2009-06-25
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+5.66%+19.59%-21.70%-32.63% 126M
+6.76%+8.82%+0.38%-60.50% 94.03M
-2.48%+2.15%+98.90%+54.10% 90.33M
+4.93%+27.35%+65.85%-11.83% 64.08M
Average +3.72%+10.58%+35.86%-12.72% 93.63M
Weighted average by Cap. +3.85%+10.26%+27.91%-15.15%

Financials

2026 *2027 *
Net sales 60.8M 70.86M 57.04M 52.12M 98.31M 6.76B 98.72M 675M 262M 3.42B 266M 260M 11.29B 42.3M 49.3M 39.68M 36.26M 68.4M 4.7B 68.68M 469M 182M 2.38B 185M 181M 7.85B
Net income 28.3M 32.98M 26.55M 24.26M 45.76M 3.15B 45.95M 314M 122M 1.59B 124M 121M 5.25B 7.75M 9.03M 7.27M 6.64M 12.53M 862M 12.58M 85.99M 33.37M 436M 33.9M 33.17M 1.44B
Net Debt -17.9M -20.86M -16.79M -15.34M -28.94M -1.99B -29.06M -199M -77.06M -1.01B -78.31M -76.6M -3.32B -47M -54.78M -44.09M -40.29M -76M -5.23B -76.31M -522M -202M -2.64B -206M -201M -8.72B
Logo CROSSJECT
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-